| Date Filed | Type | Description |
| 03/23/2023 |
4
| Saik Andrew (EVP & CFO) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.|
Txns:
| Paid exercise price by delivering 909 shares
@ $14.19, valued at
$12.9k
|
|
| 01/31/2023 |
4
| Saik Andrew (EVP & CFO) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.|
Txns:
| Granted 14,700 shares
@ $0
Granted 24,000 options to buy
@ $18.4, valued at
$441.6k
|
|
| 01/03/2023 |
4
| Saik Andrew (EVP & CFO) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.|
Txns:
| Paid exercise price by delivering 718 shares
@ $12.37, valued at
$8.9k
|
|
| 09/23/2022 |
4
| Saik Andrew (EVP & CFO) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.|
Txns:
| Paid exercise price by delivering 908 shares
@ $14.85, valued at
$13.5k
|
|
| 06/23/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/31/2022 |
4
| Saik Andrew (EVP & CFO) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.|
Txns:
| Granted 10,300 shares
@ $0
Granted 17,600 options to buy
@ $14.44, valued at
$254.1k
|
|
| 06/22/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/22/2021 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 06/02/2021 |
4
| Saik Andrew (CFO) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Granted 3,017 shares
@ $3.3575, valued at
$10.1k
|
|
| 04/02/2021 |
4
| Saik Andrew (CFO) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Paid exercise price by delivering 762 shares
@ $6.84, valued at
$5.2k
|
|
| 02/24/2021 |
4
| Saik Andrew (CFO) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Granted 29,213 shares
@ $0
Granted 68,162 options
@ $8.33, valued at
$567.8k
|
|
| 09/08/2020 |
4
| Saik Andrew (CFO) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Bought 40,000 shares
@ $1.462, valued at
$58.5k
|
|
| 05/08/2020 |
4
| Saik Andrew (CFO) has filed a Form 4 on Menlo Therapeutics Inc.|
Txns:
| Granted 250,000 shares
@ $0
Granted 250,000 options
@ $1.95, valued at
$487.5k
|
|
| 03/24/2020 |
4
| Saik Andrew (CFO) has filed a Form 4 on Menlo Therapeutics Inc.|
Txns:
| Granted 50,000 shares
@ $0
Granted 100,000 options
@ $3.13, valued at
$313k
|
|
| 03/24/2020 |
3
| Saik Andrew (CFO) has filed a Form 3 on Menlo Therapeutics Inc. |
| 02/19/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/07/2019 |
4
| Saik Andrew (CFO) has filed a Form 4 on PDS Biotechnology Corp|
Txns:
| Granted 62,715 options to buy
@ $6.39, valued at
$400.7k
|
|
| 03/18/2019 |
4
| Saik Andrew (CFO) has filed a Form 4 on Edge Therapeutics, Inc.|
Txns:
| Exercised 82,999 restricted stock units
@ $0 |
|
| 08/15/2018 |
4
| Saik Andrew (CFO) has filed a Form 4 on Edge Therapeutics, Inc.|
Txns:
| Granted 82,999 restricted stock units
@ $0 |
|
| 06/20/2018 |
4
| Saik Andrew (CFO) has filed a Form 4 on Edge Therapeutics, Inc.|
Txns:
| Granted 166,001 options to buy
@ $1.1, valued at
$182.6k
|
|
| 03/05/2018 |
4
| Saik Andrew (CFO) has filed a Form 4 on Edge Therapeutics, Inc.|
Txns:
| Granted 50,000 options to buy
@ $14.98, valued at
$749k
|
|
| 11/03/2017 |
4
| Saik Andrew (CFO) has filed a Form 4 on Edge Therapeutics, Inc.|
Txns:
| Granted 200,000 options to buy
@ $10.73, valued at
$2.1M
|
|
| 11/02/2017 |
3
| Saik Andrew (CFO) has filed a Form 3 on Edge Therapeutics, Inc. |